Patients, Physicians Rely on ChemoFx to Support Treatment Decisions
February 4, 2010
ChemoFx(R), a test produced by Precision Therapeutics, is a drug response marker that shows promising results in helping to determine individual cancer treatment plans. ChemoFx has pioneered a method of identifying cancer cell response and sensitivity to various chemotherapeutic and biologic agents at the biopsy stage, providing a custom blueprint of a patient's probable tumor response before treatment begins. The national trend has patients acting as partners in making cancer treatment decisions, and ChemoFx can help provide another layer of information to those decisions. Learn more at www.ChemoFx.com.
« Co-eXprise Closes First $2M VC Deal | | ThinkVine Helps Determine "What If" Strategies »
